JPWO2021097120A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021097120A5 JPWO2021097120A5 JP2022527146A JP2022527146A JPWO2021097120A5 JP WO2021097120 A5 JPWO2021097120 A5 JP WO2021097120A5 JP 2022527146 A JP2022527146 A JP 2022527146A JP 2022527146 A JP2022527146 A JP 2022527146A JP WO2021097120 A5 JPWO2021097120 A5 JP WO2021097120A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- atrial
- atrial fibrillation
- flutter
- epa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010003662 Atrial flutter Diseases 0.000 claims 51
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 49
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 39
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 39
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 39
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 39
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 230000007211 cardiovascular event Effects 0.000 claims 19
- 208000024891 symptom Diseases 0.000 claims 19
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 14
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 12
- 238000012544 monitoring process Methods 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 230000010036 cardiovascular benefit Effects 0.000 claims 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 2
- 229960005080 warfarin Drugs 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 208000014882 Carotid artery disease Diseases 0.000 claims 1
- 108010023302 HDL Cholesterol Proteins 0.000 claims 1
- 108010028554 LDL Cholesterol Proteins 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 229940126585 therapeutic drug Drugs 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934121P | 2019-11-12 | 2019-11-12 | |
| US62/934,121 | 2019-11-12 | ||
| US201962934879P | 2019-11-13 | 2019-11-13 | |
| US201962934952P | 2019-11-13 | 2019-11-13 | |
| US201962934637P | 2019-11-13 | 2019-11-13 | |
| US62/934,637 | 2019-11-13 | ||
| US62/934,952 | 2019-11-13 | ||
| US62/934,879 | 2019-11-13 | ||
| US201962948058P | 2019-12-13 | 2019-12-13 | |
| US62/948,058 | 2019-12-13 | ||
| US202062976683P | 2020-02-14 | 2020-02-14 | |
| US62/976,683 | 2020-02-14 | ||
| PCT/US2020/060274 WO2021097120A1 (en) | 2019-11-12 | 2020-11-12 | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022554020A JP2022554020A (ja) | 2022-12-27 |
| JPWO2021097120A5 true JPWO2021097120A5 (hu) | 2023-11-21 |
Family
ID=75846184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022527146A Pending JP2022554020A (ja) | 2019-11-12 | 2020-11-12 | 心房細動および／または心房粗動を患う対象における心血管イベントのリスクを低減する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210137879A1 (hu) |
| EP (1) | EP4058141A4 (hu) |
| JP (1) | JP2022554020A (hu) |
| KR (1) | KR20220122616A (hu) |
| CN (2) | CN116350616A (hu) |
| AU (1) | AU2020382610A1 (hu) |
| BR (1) | BR112022009189A2 (hu) |
| CA (1) | CA3160676A1 (hu) |
| IL (1) | IL292821A (hu) |
| MX (1) | MX2022005467A (hu) |
| WO (1) | WO2021097120A1 (hu) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
| NZ620473A (en) | 2009-06-15 | 2015-09-25 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides without raising ldl-c levels |
| US20140127289A1 (en) | 2010-11-29 | 2014-05-08 | Armarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| EP3750536A1 (en) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
| WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1589930A2 (en) * | 2003-01-08 | 2005-11-02 | Flacco-Nesselroad Family Trust | Combination therapy for anticoagulation |
| NZ620473A (en) * | 2009-06-15 | 2015-09-25 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides without raising ldl-c levels |
| UA118015C2 (uk) * | 2012-06-29 | 2018-11-12 | Амарін Фармасьютікалз Айрленд Лімітед | Способи зменшення ризику розвитку серцево-судинної події у суб'єкта, що одержує терапію статином |
| US20160135702A1 (en) * | 2013-06-21 | 2016-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Techniques for Predicting Cardiac Arrhythmias Based on Signals from Leads of Electrocardiography |
| WO2016117621A1 (ja) * | 2015-01-21 | 2016-07-28 | 持田製薬株式会社 | ω３脂肪酸の自己乳化組成物 |
-
2020
- 2020-11-12 WO PCT/US2020/060274 patent/WO2021097120A1/en unknown
- 2020-11-12 CN CN202211705517.1A patent/CN116350616A/zh active Pending
- 2020-11-12 BR BR112022009189A patent/BR112022009189A2/pt not_active Application Discontinuation
- 2020-11-12 AU AU2020382610A patent/AU2020382610A1/en active Pending
- 2020-11-12 KR KR1020227019295A patent/KR20220122616A/ko unknown
- 2020-11-12 EP EP20888153.2A patent/EP4058141A4/en active Pending
- 2020-11-12 JP JP2022527146A patent/JP2022554020A/ja active Pending
- 2020-11-12 CN CN202080092982.5A patent/CN114980973A/zh active Pending
- 2020-11-12 MX MX2022005467A patent/MX2022005467A/es unknown
- 2020-11-12 CA CA3160676A patent/CA3160676A1/en active Pending
- 2020-11-12 US US17/096,808 patent/US20210137879A1/en active Pending
-
2022
- 2022-05-08 IL IL292821A patent/IL292821A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3064013B2 (ja) | 斑形成疾患の治療のための方法及び材料 | |
| Larson | Prospects for delaying the rising tide of worldwide, late-life dementias | |
| KR102412997B1 (ko) | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 | |
| JP2011518785A (ja) | 心血管入院または死亡の予防に用いる薬剤を調製するためのドロネダロンの使用 | |
| JPWO2021097120A5 (hu) | ||
| Perahia et al. | Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial. | |
| JP2011529958A (ja) | 脳卒中または一過性脳虚血発作を予防するための薬物を調製するためのドロネダロンの使用 | |
| KR20170104597A (ko) | 신경근육, 신경퇴행, 자가면역, 발달 및/또는 대사 질환의 치료를 위한 뇌 유도된 신경친화성 인자(bdnf)의 유도된 발현 | |
| JP2024056786A (ja) | チルゼパチドの治療的使用 | |
| Lee et al. | Add-on and withdrawal effect of pravastatin on proteinuria in hypertensive patients treated with AT1 receptor blockers | |
| JP2011518147A (ja) | 血中カリウム濃度を調節する薬剤を調製するためのドロネダロンまたは医薬的に許容されるこの塩の使用 | |
| Guo et al. | Pterostilbene protects the optic nerves and retina in a murine model of experimental autoimmune encephalomyelitis via activation of SIRT1 signaling | |
| Kario et al. | Management of cardiovascular risk in disaster: Jichi Medical School (JMS) Proposal 2004 | |
| TW201320994A (zh) | 投藥療程 | |
| TOLBA et al. | THEEFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETES MELLITUS | |
| JP2005132799A (ja) | 本態性振戦の予防・治療剤 | |
| Kumar et al. | Unmasking of familial long QT syndrome type 2 with crystal methamphetamine exposure | |
| WO2006011495A1 (ja) | 高コレステロール血症及び／又は高トリグリセリド血症治療剤 | |
| JP2020523408A5 (hu) | ||
| Muls et al. | Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates | |
| RU2702128C1 (ru) | Лекарственное средство, фармацевтическая композиция, активный ингредиент фармацевтической композиции и способ лечения тревоги и депрессии у больных острым инфарктом миокарда | |
| Van Lith et al. | Opipramol in the climacteric syndrome. A double-blind, placebo-controlled trial | |
| JP2003510284A (ja) | アテローム性動脈硬化症の処置のための併用療法 | |
| Miller et al. | Sleep, inflammation, and disease | |
| Kukopulos et al. | Lithium non-responders and their treatment |